Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société BASILEA PHARMACEUTICA AG
09/30BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma filed New Drug Application for the mark..
AQ
08/17BASILEA PHARMACEUTICA : reports strong financial results for half-year 2021 with significa..
AQ
07/26BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma prepares NDA filing for the marketing a..
AQ
07/14BASILEA PHARMACEUTICA : announces distribution agreement with JSC Lancet for antibiotic Ze..
AQ
04/21BASILEA PHARMACEUTICA : shareholders approve all proposals of the board of directors at th..
AQ
02/24BASILEA PHARMACEUTICA : successfully placed 1 million new registered shares, raising gross..
AQ
2020BASILEA PHARMACEUTICA : reports acceptance for regulatory review of Pfizer's marketing aut..
AQ
2020BASILEA PHARMACEUTICA : reports acceptance for regulatory review of Pfizer's marketing aut..
AQ
2020BASILEA PHARMACEUTICA : announces approval of antibiotic Zevtera® in China to treat commun..
AQ
2020BASILEA PHARMACEUTICA : announces approval of antibiotic Zevtera® in China to treat commun..
AQ
2020Basilea announces approval of antibiotic Zevtera® in China to treat community-acquired ..
GL
2020BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreement with E..
AQ
2020BASILEA PHARMACEUTICA : announces Clinical Trial Collaboration and Supply Agreement with E..
AQ
2020Basilea announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and ..
GL
2020BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of derazanti..
AQ
2020BASILEA PHARMACEUTICA : presents preclinical data on anti-angiogenic activity of derazanti..
AQ
2020Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 20..
GL
2020BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 exploring de..
AQ
2020BASILEA PHARMACEUTICA : reports interim results from phase 1/2 study FIDES-02 exploring de..
AQ
2020Basilea reports interim results from phase 1/2 study FIDES-02 exploring derazantinib in..
GL
2020BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA patients wit..
AQ
2020BASILEA PHARMACEUTICA : reports pooled efficacy data for derazantinib in iCCA patients wit..
AQ
2020Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene ..
GL
2020BASILEA PHARMACEUTICA : initiates targeted biomarker-driven phase 2 study with lisavanbuli..
AQ
2020BASILEA PHARMACEUTICA : initiates targeted biomarker-driven phase 2 study with lisavanbuli..
AQ
2020Basilea initiates targeted biomarker-driven phase 2 study with lisavanbulin in patients..
GL
2020BASILEA PHARMACEUTICA : starts phase 1/2 study FIDES-03 with derazantinib in patients with..
AQ
2020BASILEA PHARMACEUTICA : starts phase 1/2 study FIDES-03 with derazantinib in patients with..
AQ
2020Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric canc..
GL
2020BASILEA PHARMACEUTICA : reports data from poster presentations at ESMO Virtual Congress 20..
AQ
2020BASILEA PHARMACEUTICA : reports data from poster presentations at ESMO Virtual Congress 20..
AQ
2020Basilea reports data from poster presentations at ESMO Virtual Congress 2020
GL
2020Basilea reports strong financial results for half-year 2020, progress in R&D portfolio ..
GL
2020BASILEA PHARMACEUTICA : reports acceptance for regulatory review of Pfizer's marketing aut..
AQ
2020Basilea reports acceptance for regulatory review of Pfizer's marketing authorization ap..
GL
2020Basilea announces completion of its transaction involving a partial repurchase of its e..
GL
2020Basilea announces data presentations at ESMO Virtual Congress 2020
GL
2020Basilea announces a conversion price of CHF 62.50 for its New Bonds and the acceptance ..
GL
2020Basilea announces completion of patient enrolment into first cohort of phase 2 study FI..
GL
2020Basilea continues with the implementation of the Repurchase Offer and the issuance of N..
GL
2020Basilea Bonds tendered in an aggregate principal amount of approximately CHF 47 million
GL
2020Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggerin..
GL
2020Basilea announces the start of the offer period of its partial repurchase offer for its..
GL
2020Basilea announces move of corporate headquarters to Allschwil, canton of Basel-Landscha..
GL
2020BASILEA PHARMACEUTICA : announces partial repurchase offer for at least CHF 90 million and..
AQ
2020Basilea successfully places CHF 125 million senior convertible bonds
GL
2020Basilea launches the placement of CHF 100 million senior convertible bonds with an incr..
GL
2020Basilea enters into sale and leaseback agreement for corporate headquarters building
GL
2020Basilea receives CHF 5 million milestone payment related to marketing authorization of ..
GL
2020Basilea provides corporate update
GL
2020Basilea announces appointment of new Head of Global Quality Management
GL
2020Basilea shareholders approve all proposals of the Board of Directors at the Annual Gene..
GL
2020Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Australia trigger..
GL
2020Basilea reports significant revenue growth from marketed products and pipeline progress..
GL
2020Basilea reports activity of derazantinib in preclinical models of gastric cancer at ASC..
GL
2020Basilea announces clinical supply agreement for its planned study FIDES-03 with derazan..
GL
2020Basilea reports total revenue exceeding guidance driven by higher than expected contrib..
GL
2020Basilea at the 38th Annual J. P. Morgan Healthcare Conference – significant progr..
GL
2019Basilea plans progression of oncology candidate lisavanbulin to targeted, biomarker-dri..
GL
2019Continued strong Cresemba® (isavuconazole) sales trigger second sales milestone this ye..
GL
2019Basilea reports positive preclinical data on oncology drug candidates derazantinib and ..
GL
2019Basilea reports marketing authorization of antifungal Cresemba® in Brazil
GL
2019Basilea reports at ESMO meeting that drug candidate derazantinib showed clinical benefi..
GL
2019Basilea announces completion of patient enrolment in phase 1 study with oral BAL101553 ..
GL
2019Basilea reports significantly increased cash-generating revenue, flat operating expense..
GL
2019Basilea starts phase 1/2 study with derazantinib in urothelial cancer
GL
2019Basilea extends phase 2 study with derazantinib in intrahepatic bile duct cancer (iCCA)..
GL
2019Basilea reports publication of clinical data for anticancer drug candidates BAL101553 i..
GL
2019BASILEA PHARMACEUTICA : Forge And Basilea Enter Into Multi-Target Agreement To Discover An..
PR
2019Strong European Cresemba® (isavuconazole) sales trigger USD 5 million milestone payment..
GL
2019BASILEA PHARMACEUTICA : announces change in the Management Committee - Adesh Kaul appointe..
GL
2019Basilea announces change in the Management Committee - Adesh Kaul appointed CFO
GL
2019Basilea announces collaboration to study derazantinib and atezolizumab (Tecentriq®) in ..
GL
2019BASILEA PHARMACEUTICA : announces collaboration to study derazantinib and atezolizumab (Te..
GL
2019Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for..
GL
1  2  3  4Next
Upcoming event on BASILEA PHARMACEUTICA AG
Upcoming sector events